All about NASH: disease biology, targets, and opportunities on the road to NASH drugs.
作者信息
Xu H Eric, Guo Jin-Song
机构信息
Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
DrugTimes Team, BioSeed (Shanghai) Biotechnology Co., Ltd., Shanghai, 201203, China.
出版信息
Acta Pharmacol Sin. 2022 May;43(5):1101-1102. doi: 10.1038/s41401-022-00900-y. Epub 2022 Apr 4.
Abstract
摘要
相似文献
1
All about NASH: disease biology, targets, and opportunities on the road to NASH drugs.
Acta Pharmacol Sin. 2022 May;43(5):1101-1102. doi: 10.1038/s41401-022-00900-y. Epub 2022 Apr 4.
2
Improving the economics of NASH/NAFLD treatment through the use of systems biology.
Drug Discov Today. 2017 Oct;22(10):1532-1538. doi: 10.1016/j.drudis.2017.07.005. Epub 2017 Jul 20.
3
Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313.
4
Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Curr Vasc Pharmacol. 2018;16(3):276-288. doi: 10.2174/1570161115666170621083744.
5
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4.
6
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
Acta Pharmacol Sin. 2022 May;43(5):1103-1119. doi: 10.1038/s41401-022-00880-z. Epub 2022 Feb 25.
7
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Diabetologia. 2016 Jun;59(6):1112-20. doi: 10.1007/s00125-016-3952-1. Epub 2016 Apr 21.
8
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Cells. 2019 Dec 21;9(1):37. doi: 10.3390/cells9010037.
9
Promising therapies for treatment of nonalcoholic steatohepatitis.
Expert Opin Emerg Drugs. 2016 Sep;21(3):343-57. doi: 10.1080/14728214.2016.1220533. Epub 2016 Aug 28.
10
NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Clin Mol Hepatol. 2017 Jun;23(2):103-108. doi: 10.3350/cmh.2017.0103. Epub 2017 May 10.
引用本文的文献
1
A UFD1 variant encoding a microprotein modulates UFD1f and IPMK ubiquitination to play pivotal roles in anti-stress responses.
Nat Commun. 2025 Jul 21;16(1):6695. doi: 10.1038/s41467-025-62073-6.
2
The Yin-Yang functions of macrophages in metabolic disorders.
Life Med. 2022 Aug 30;1(3):319-332. doi: 10.1093/lifemedi/lnac035. eCollection 2022 Dec.
3
Main factors influencing long-term outcomes of liver transplantation in 2022.
World J Hepatol. 2023 Mar 27;15(3):321-352. doi: 10.4254/wjh.v15.i3.321.
本文引用的文献
1
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
Acta Pharmacol Sin. 2022 May;43(5):1103-1119. doi: 10.1038/s41401-022-00880-z. Epub 2022 Feb 25.
2
The role of REV-ERB in NASH.
Acta Pharmacol Sin. 2022 May;43(5):1133-1140. doi: 10.1038/s41401-022-00883-w. Epub 2022 Feb 25.
3
FXR: structures, biology, and drug development for NASH and fibrosis diseases.
Acta Pharmacol Sin. 2022 May;43(5):1120-1132. doi: 10.1038/s41401-021-00849-4. Epub 2022 Feb 25.
4
Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.
Acta Pharmacol Sin. 2022 May;43(5):1180-1190. doi: 10.1038/s41401-022-00860-3. Epub 2022 Feb 21.
5
Histological assessment based on liver biopsy: the value and challenges in NASH drug development.
Acta Pharmacol Sin. 2022 May;43(5):1200-1209. doi: 10.1038/s41401-022-00874-x. Epub 2022 Feb 14.
6
NASH: regulatory considerations for clinical drug development and U.S. FDA approval.
Acta Pharmacol Sin. 2022 May;43(5):1210-1214. doi: 10.1038/s41401-021-00832-z. Epub 2022 Jan 21.
7
Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH.
Acta Pharmacol Sin. 2022 May;43(5):1141-1155. doi: 10.1038/s41401-022-00864-z. Epub 2022 Feb 1.
8
GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
Acta Pharmacol Sin. 2022 May;43(5):1156-1166. doi: 10.1038/s41401-021-00836-9. Epub 2021 Dec 21.
9
Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis.
Acta Pharmacol Sin. 2022 May;43(5):1191-1199. doi: 10.1038/s41401-021-00822-1. Epub 2021 Dec 14.
10
The miR-23-27-24 cluster: an emerging target in NAFLD pathogenesis.
Acta Pharmacol Sin. 2022 May;43(5):1167-1179. doi: 10.1038/s41401-021-00819-w. Epub 2021 Dec 10.
Zotero 插件